Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04544098 · ClinicalTrials.gov registry record · Early Phase 1
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
A Early Phase 1 study of Neuroendocrine Tumors and Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04544098: Active Early Phase 1 study of Neuroendocrine Tumors and Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04544098 is a Early Phase 1 study of Neuroendocrine Tumors and Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04544098, a Early Phase 1 study of Neuroendocrine Tumors and Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in the arm). The researchers will also determine whether Lutathera is effective against participants' cancer.
Primary Outcome
Feasibility will be defined as at least 7 or more patients out of 10 patients who successfully complete 2 IA injections.
Conditions Studied
Interventions
- DRUG 177Lu-DOTATATE
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
What the registry record for NCT04544098 still lists
NCT04544098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which 177Lu-DOTATATE is the first listed.
NCT04544098 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04544098 about?
NCT04544098 is a clinical study titled "Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver". This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in...
What is the current status of trial NCT04544098?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-09-02. Estimated completion is 2026-09.
What conditions does trial NCT04544098 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors.
What interventions are being tested in trial NCT04544098?
The interventions under investigation include: 177Lu-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT04544098?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04544098 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04544098's enrollment target sits among peer trials
10 50th of 52 higher than 2 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
COMPLETED · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI